China’s NMPA approves AstraZeneca’s Calquence for lymphocytic leukaemia
The approval was based on the findings from the ASCEND global Phase 3 trial and a Phase 1/2…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Sep 23
The approval was based on the findings from the ASCEND global Phase 3 trial and a Phase 1/2…
04 Sep 23
Letybo is a product in the Korean botulinum toxin market that has successfully entered global markets like China,…
04 Sep 23
Lupin Pharma Canada Ltd., a wholly-owned subsidiary of Lupin Limited (Lupin), today announced the launch of Propranolol LA…
04 Sep 23
Leslie McDonnell has been elected Member of Mölnlycke AB's Board of Directors on 1 September 2023.
04 Sep 23
ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung…
04 Sep 23
Brain Navi announced today the demonstration of NaoTrac, a neurosurgical navigation robot and KrystoLens, a single-use neuro-endoscope at CNS…
01 Sep 23
RELiZORB is the only enzyme product cleared by the FDA for use with enteral feeding
01 Sep 23
The ACTIMIS clinical trial evaluating glenzocimab in combination with the reference treatment in patients presenting with AIS has…
01 Sep 23
Interview with Alicia Martínez (PhD), CEO, Time is Brain
31 Aug 23
The CHMP's opinion was based on the full body of prior clinical, non-clinical, and real-world data supporting the…